Sickle Cell Disease (SCD) – Overview

Sickle Cell Disease (SCD) is an inherited hematological condition caused by a mutation in the hemoglobin gene, leading to the production of abnormal hemoglobin S.

Health Apr 21, 2025 16 Add to Reading List

This causes the red blood cells to adopt a rigid, sickle-like shape, which obstructs blood flow and diminishes oxygen delivery to tissues. The disorder is associated with ongoing pain, anemia, higher susceptibility to infections, organ damage, and various other severe complications. SCD predominantly affects individuals of African, Mediterranean, Middle Eastern, and Indian origin. Management strategies focus on alleviating symptoms, preventing complications, and improving life quality through advanced treatments and comprehensive care.

Simplified, visualized, and ready for you—see the infographic!: Click Here

Epidemiological Segmentation of SCD (2020–2034) – 6MM

Total Prevalence
Diagnosed Prevalence
Prevalence by SCD Type
Number of Treated Cases

SCD Epidemiology (2023 Insights)
In 2023, an estimated 161,000 individuals in the six major markets (6MM) were living with Sickle Cell Disease.

The United States reported approximately 65% of these cases, highlighting the significant burden of the disease in the country.

The highest prevalence was observed in the 18–44 age group within the U.S., indicating the disease's impact on younger, working-age individuals.

SCD Market Overview
The market for Sickle Cell Disease in the 6MM was valued at an estimated USD 650 million in 2023.

Market Drivers

Advances in gene-editing technologies and disease-modifying therapies are transforming the SCD treatment landscape, offering the potential for long-term benefits.
Increased awareness, earlier detection, and stronger support from governments and advocacy organizations are helping drive market growth and enhancing patient access to care.

Market Challenges

High treatment costs and limited healthcare infrastructure in low-income areas impede access to advanced therapies.
Complexities in regulatory approvals and clinical trials may slow the pace of new treatment developments.

Explore key stats, market drivers, and emerging drugs—all in one visual!: Click Here

Promising Emerging Therapies